DE602004022170D1 - 2-imino-4-(thio)oxo-5-polycyclovinylazoline zur verwendung als pi3-kinase-inhibtoren - Google Patents

2-imino-4-(thio)oxo-5-polycyclovinylazoline zur verwendung als pi3-kinase-inhibtoren

Info

Publication number
DE602004022170D1
DE602004022170D1 DE602004022170T DE602004022170T DE602004022170D1 DE 602004022170 D1 DE602004022170 D1 DE 602004022170D1 DE 602004022170 T DE602004022170 T DE 602004022170T DE 602004022170 T DE602004022170 T DE 602004022170T DE 602004022170 D1 DE602004022170 D1 DE 602004022170D1
Authority
DE
Germany
Prior art keywords
polycyclovinylazoline
imino
thio
oxo
kinase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004022170T
Other languages
German (de)
English (en)
Inventor
Thomas Rueckle
Jeffrey Shaw
Dennis Church
David Covini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono SA filed Critical Merck Serono SA
Publication of DE602004022170D1 publication Critical patent/DE602004022170D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE602004022170T 2003-07-28 2004-07-27 2-imino-4-(thio)oxo-5-polycyclovinylazoline zur verwendung als pi3-kinase-inhibtoren Expired - Lifetime DE602004022170D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03102313 2003-07-28
PCT/EP2004/051625 WO2005011686A1 (en) 2003-07-28 2004-07-27 2-imino-4-(thio) oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors

Publications (1)

Publication Number Publication Date
DE602004022170D1 true DE602004022170D1 (de) 2009-09-03

Family

ID=34112474

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004022170T Expired - Lifetime DE602004022170D1 (de) 2003-07-28 2004-07-27 2-imino-4-(thio)oxo-5-polycyclovinylazoline zur verwendung als pi3-kinase-inhibtoren

Country Status (9)

Country Link
US (1) US8106214B2 (cg-RX-API-DMAC7.html)
EP (1) EP1648452B1 (cg-RX-API-DMAC7.html)
JP (1) JP4908210B2 (cg-RX-API-DMAC7.html)
CA (1) CA2531140C (cg-RX-API-DMAC7.html)
DE (1) DE602004022170D1 (cg-RX-API-DMAC7.html)
ES (1) ES2328146T3 (cg-RX-API-DMAC7.html)
IL (1) IL173195A (cg-RX-API-DMAC7.html)
NO (1) NO332434B1 (cg-RX-API-DMAC7.html)
WO (1) WO2005011686A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070249599A1 (en) * 2004-02-25 2007-10-25 Duffy Kevin J Novel Chemical Compounds
RU2007103709A (ru) 2004-07-01 2008-08-10 Ф.Хоффманн-Ля Рош Аг (Ch) Тиазолинонхинолины
KR101229647B1 (ko) * 2004-09-03 2013-02-05 메르크 세로노 에스.에이. 피리딘 메틸렌 아조리디논 및 포스포이노시타이드 저해제의용도
US7241893B2 (en) * 2004-09-17 2007-07-10 Hoffman-La Roche Inc. Thiazolinone 2-substituted quinolines
US7253285B2 (en) * 2004-09-17 2007-08-07 Hoffmann-La Roche Inc. Thiazolinone 4-monosubstituted quinolines
WO2006040050A1 (en) * 2004-10-14 2006-04-20 F.Hoffmann-La Roche Ag Quinazolinylmethylene thiazolinones as cdk1 inhibitors
US7304074B2 (en) * 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
TW200716580A (en) * 2005-06-08 2007-05-01 Smithkline Beecham Corp (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one
CA2618489A1 (en) * 2005-09-07 2007-03-15 Laboratoires Serono S.A. Pi3k inhibitors for the treatment of endometriosis
CN101300047A (zh) * 2005-09-07 2008-11-05 雪兰诺实验室有限公司 Pi3k抑制剂用于子宫内膜异位症的治疗
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
WO2007113005A2 (en) * 2006-04-03 2007-10-11 European Molecular Biology Laboratory (Embl) 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors
AR060391A1 (es) * 2006-04-11 2008-06-11 Smithkline Beecham Corp Compuestos de quinolin tiazolidinadiona, sustituidos con heterociclos, composiciones farmaceuticas que los contienen y usos para preparar medicamentos que inhiben la actividad de pi3 quinasas.
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
US20080255115A1 (en) * 2007-04-11 2008-10-16 Michael Gerard Darcy Thiazolidinedione derivatives as pi3 kinase inhibitors
TW200902008A (en) * 2007-05-10 2009-01-16 Smithkline Beecham Corp Quinoxaline derivatives as PI3 kinase inhibitors
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
FR2919608B1 (fr) * 2007-08-01 2012-10-05 Univ Rennes Derives d'imidazolones,procede de preparation et applications biologiques
PE20091624A1 (es) 2008-03-03 2009-11-19 Takeda Pharmaceutical Farmaco combinado a base de un inhibidor de her2 derivado de pirrolopirimidina o pirazolopirimidina
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
US9062046B2 (en) * 2010-07-16 2015-06-23 Piramal Enterprises Limited Substituted imidazoquinoline derivatives as kinase inhibitors
CN102584809B (zh) * 2011-01-14 2014-12-24 湘北威尔曼制药股份有限公司 胺基噻唑烷酮化合物及其制备方法与在制备抗肿瘤药物中的应用
WO2014021337A1 (ja) 2012-07-30 2014-02-06 国立大学法人京都大学 精神神経疾患又は悪性腫瘍に関する化合物及び医薬組成物
US10310802B2 (en) * 2014-03-26 2019-06-04 Unanimous A. I., Inc. System and method for moderating real-time closed-loop collaborative decisions on mobile devices
CN106588909B (zh) * 2017-01-06 2019-08-27 广东工业大学 一种喹啉类衍生物的制备及其在抗炎中的应用
MX2020010999A (es) 2018-04-18 2021-01-20 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
PE20220562A1 (es) 2019-07-24 2022-04-13 Constellation Pharmaceuticals Inc Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH052200A (ja) 1990-09-28 1993-01-08 Toshiba Corp 有機非線形光学材料
JP3871354B2 (ja) * 1994-07-29 2007-01-24 株式会社フジモト・コーポレーション 新規な2−(n−シアノイミノ)チアゾリジン−4−オン誘導体
MXPA05000453A (es) * 2002-07-10 2005-03-23 Applied Research Systems Derivados de benceno fusionados a azolidinona-vinilo.
KR20050085115A (ko) * 2002-11-22 2005-08-29 스미스클라인 비참 코포레이션 신규 화합물
KR101229647B1 (ko) 2004-09-03 2013-02-05 메르크 세로노 에스.에이. 피리딘 메틸렌 아조리디논 및 포스포이노시타이드 저해제의용도

Also Published As

Publication number Publication date
JP4908210B2 (ja) 2012-04-04
IL173195A (en) 2013-04-30
EP1648452A1 (en) 2006-04-26
EP1648452B1 (en) 2009-07-22
NO332434B1 (no) 2012-09-17
JP2007500171A (ja) 2007-01-11
US8106214B2 (en) 2012-01-31
CA2531140A1 (en) 2005-02-10
WO2005011686A1 (en) 2005-02-10
NO20060573L (no) 2006-02-03
CA2531140C (en) 2013-06-18
US20070021447A1 (en) 2007-01-25
IL173195A0 (en) 2006-06-11
AU2004260836A1 (en) 2005-02-10
ES2328146T3 (es) 2009-11-10

Similar Documents

Publication Publication Date Title
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
ATE492544T1 (de) Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
CY2013014I2 (el) Εναντιομερικως καθαρες αμινοετεροαρυλικες ενωσεις ως αναστολεις πρωτεϊνικης κινασης
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
AP2114A (en) Aminoheteroaryl compounds as protein kinase inhibitors
IS7599A (is) Heterósýklískir kínasatálmar
DE602007008837D1 (de) Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
DE602007014374D1 (de) Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer
ATE524467T1 (de) Neuartige aza-heterozyklen als kinase-inhibitoren
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
IS7646A (is) Azaindól kínasatálmar
ATE518860T1 (de) Pyrroloä2,3-büpyridinderivate als proteinkinaseinhibitoren
ZA200709269B (en) Protein kinase inhibitors
ATE530545T1 (de) Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
ATE509011T1 (de) Pyrimidinderivate als 11beta-hsd1-inhibitoren
DE60322544D1 (de) Glycinamid-derivate als raf-kinase-hemmer
ATE493403T1 (de) Kinaseinhibitoren
ATE433449T1 (de) Kinaseinhibitoren
SI2476667T1 (sl) Aminoheteroarilne spojine kot inhibitorji protein-kinaze
ATE302781T1 (de) Sulfamidothienopyrimidine zur verwendung als phosphodiesterase v-hemmer
ZA200703835B (en) Heterocyclic substituted bisarylurea derivatives as kinase inhibitors
ATE468338T1 (de) Pyrrolochinolinderivate und ihre verwendung als proteinkinasehemmer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition